公开(公告)号：EP3207027A4

公开(公告)日：2018-04-18

申请号：EP15850792

申请日：2015-10-16

Applicant: UNIV MELBOURNE

Inventor： DONNELLY PAUL STEPHEN ,  RUDD STACEY ERIN ,  WILLIAMS SPENCER JOHN

IPC: C07C235/80 ,  A61K51/10 ,  A61K103/00 ,  A61K103/20 ,  A61K103/30 ,  C07C247/14 ,  C07C261/02 ,  C07K17/06

CPC classification number: A61K31/18 ,  A61K51/1051 ,  C07C259/06 ,  C07C309/14 ,  C07C311/19 ,  C07C311/29 ,  C07C311/42 ,  C07C311/46 ,  C07C323/60 ,  C07C2601/04 ,  C07D207/48 ,  C07D211/60 ,  C07D211/96 ,  C07D213/42 ,  C07D213/74 ,  C07D213/89 ,  C07D215/36 ,  C07D223/06 ,  C07D277/06 ,  C07D277/80 ,  C07D279/12 ,  C07D295/13 ,  C07D309/06 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D453/06 ,  C07D471/08 ,  C07D487/08

Abstract: The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.

公开(公告)号：EP2880030A4

公开(公告)日：2016-01-13

申请号：EP13824843

申请日：2013-08-05

Applicant: SUNSHINE LAKE PHARMA CO LTD

Inventor： ZHANG YINGJUN ,  ZHANG JIANCUN ,  XIE HONGMING ,  REN QINGYUN ,  TAN YUMEI ,  LUO HUICHAO

IPC: C07D403/14 ,  A61K31/4025 ,  A61K31/4178 ,  A61P31/12 ,  C07D401/14 ,  C07D405/14

CPC classification number: C07D403/14 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/06 ,  C07D471/08 ,  C07D491/056 ,  C07D491/113 ,  C07D493/08 ,  C07D519/00

Abstract: Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

Abstract translation: 本文提供的是具有式（I）化合物或其立体异构体，几何异构体，互变异构体，N-氧化物，水合物，溶剂合物，代谢物，药学上可接受的盐或前药，其可用于 治疗HCV感染或HCV病症。 本文还提供了包含本文公开的化合物的药物组合物，其可用于治疗HCV感染或HCV病症。

公开(公告)号：EP2187888B1

公开(公告)日：2015-10-21

申请号：EP08795126.5

申请日：2008-08-08

Applicant: CORTEX PHARMACEUTICALS, INC.

Inventor： MUELLER, Rudolf ,  STREET, Leslie

IPC: A61K31/519 ,  A61K31/53 ,  C07D498/04 ,  C07D265/24 ,  A61P25/28

CPC classification number: A61K31/46 ,  A61K31/4245 ,  A61K31/439 ,  A61K31/519 ,  A61K31/53 ,  A61K45/06 ,  C07D209/52 ,  C07D451/02 ,  C07D451/04 ,  C07D451/06 ,  C07D453/06 ,  C07D471/08 ,  C07D487/08 ,  C07D491/08

公开(公告)号：EP2886540A4

公开(公告)日：2015-06-24

申请号：EP13829720

申请日：2013-08-14

Applicant: XUANZHU PHARMA CO LTD

Inventor： WU FRANK ,  WANG AICHEN

IPC: C07D403/14 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/55 ,  A61P13/02 ,  A61P15/10 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D453/06 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10 ,  C07D498/08

CPC classification number: C07D491/08 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/00 ,  C07D239/47 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D453/06 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10 ,  C07D498/08

公开(公告)号：EP2880030A1

公开(公告)日：2015-06-10

申请号：EP13824843.0

申请日：2013-08-05

Applicant: Sunshine Lake Pharma Co., Ltd.

Inventor： ZHANG, Yingjun ,  ZHANG, Jiancun ,  XIE, Hongming ,  REN, Qingyun ,  TAN, Yumei ,  LUO, Huichao

IPC: C07D403/14 ,  C07D401/14 ,  A61K31/4178 ,  A61K31/4025 ,  A61P31/12

CPC classification number: C07D403/14 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/06 ,  C07D471/08 ,  C07D491/056 ,  C07D491/113 ,  C07D493/08 ,  C07D519/00

Abstract: Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

公开(公告)号：EP2480078A4

公开(公告)日：2013-03-06

申请号：EP10819490

申请日：2010-09-23

Applicant: MEDIVATION TECHNOLOGIES INC

Inventor： JAIN RAJENDRA PARASMAL ,  CHAKRAVARTY SARVAJIT

IPC: A61K31/40 ,  A61P25/00 ,  C07D471/04 ,  C07D471/14 ,  C07D471/18 ,  C07D471/22

CPC classification number: C07D471/22 ,  C07D453/06 ,  C07D455/00 ,  C07D471/04 ,  C07D471/14 ,  C07D471/18

公开(公告)号：EP2141990A1

公开(公告)日：2010-01-13

申请号：EP08744466.7

申请日：2008-03-27

Applicant: High Point Pharmaceuticals, LLC

Inventor： EBDRUP, Soren ,  TONDER, Janne Ejrnaes ,  ANDERSEN, Henrik Sune

IPC: A01N43/38 ,  A61K31/40 ,  A61K31/38

CPC classification number: C07D451/06 ,  C07C233/74 ,  C07C2603/74 ,  C07D209/02 ,  C07D209/88 ,  C07D307/91 ,  C07D453/06 ,  C07D471/08

Abstract: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β -hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

Abstract translation: 描述了一类新的通式（I）化合物，它们在治疗中的用途，包含该化合物的药物组合物，以及它们在药物制备中的用途。 本发明化合物调节11β-羟基类固醇脱氢酶1型（11βHSD1）的活性，因此可用于治疗其中这种调节是有益的疾病，例如， 代谢综合征。

公开(公告)号：EP1819342A4

公开(公告)日：2008-12-17

申请号：EP05852416

申请日：2005-11-29

Applicant: MERCK & CO INC

Inventor： DEVITA ROBERT J ,  JIANG JINLONG ,  MILLS SANDER G

IPC: A61K31/535 ,  A61P25/00 ,  C07D207/04 ,  C07D211/70 ,  C07D215/20 ,  C07D215/38 ,  C07D215/48 ,  C07D215/60 ,  C07D453/06

CPC classification number: C07D215/20 ,  C07D215/38 ,  C07D215/48 ,  C07D215/60 ,  C07D453/06

公开(公告)号：EP1994015A1

公开(公告)日：2008-11-26

申请号：EP07705669.5

申请日：2007-02-28

Applicant: Pfizer Products Inc.

Inventor： CHANG, George ,  GARIGIPATI, Ravi, Shanker ,  LEFKER, Bruce, Allen ,  PERRY, David, Austen

IPC: C07D257/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  A61K31/40 ,  A61P9/00 ,  C07D417/12 ,  C07D453/06 ,  C07D471/04 ,  C07D491/04 ,  C07D513/04 ,  C07D413/12

CPC classification number: C07D257/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D453/06 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D513/04

Abstract: Dibenzyl amine compounds and derivatives, of Formula (I), pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

Abstract translation: 式（I）的二苄基胺化合物和衍生物，含有这些化合物的药物组合物和这些化合物用于提高某些血浆脂质水平（包括高密度脂蛋白 - 胆固醇）并降低某些其他血浆脂质水平如LDL-胆固醇的用途 和甘油三酯，并因此治疗某些哺乳动物（包括人类）中由低HDL胆固醇和/或高水平的LDL-胆固醇和甘油三酯（例如动脉粥样硬化和心血管疾病）加剧的疾病。

公开(公告)号：EP1879887A2

公开(公告)日：2008-01-23

申请号：EP06743700.4

申请日：2006-04-14

Applicant: Cerep

Inventor： BOTEZ, Iuliana ,  DAVID-BASEI, Christelle ,  GOURLAOUËN, Nelly ,  NICOLAÏ, Eric ,  BALAVOINE, Fabrice ,  VALETTE, Gérard ,  SERRADEIL-LE GAL, Claudine

IPC: C07D417/12 ,  C07D401/12 ,  C07D413/12 ,  C07D453/06 ,  C07D471/08 ,  C07D211/42 ,  C07D211/46 ,  A61K31/452 ,  A61P3/00

CPC classification number: C07D295/088 ,  C07D211/42 ,  C07D211/46 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D453/06 ,  C07D471/08

Abstract: The invention relates to novel compounds, to the preparation and use thereof, in particular therapeutic. Said invention particularly relates to derived compounds comprising at least two aromatic cycles, to the preparation and use thereof, mainly for human and animal health care. Said compounds exhibit an affinity to biological receptors Y and NPY of a neuropeptide Y which are present in the central and peripheral nervous systems. The inventive compounds are preferably embodied in the form NPY antagonists, and more particularly in the form of NPY Y1 subtype antagonists and, whereby are usable in therapeutic or prophylactic treatment all NPY involving disorders. Pharmaceutical compositions comprising said compounds, the preparation and the use thereof and treating methods using said compounds are also disclosed.